Expert Interview
Checking in on the cystic fibrosis landscape with a prescriber of Vertex' Kalydeco, Orkambi, and Symdeko
Ticker(s): VRTXInstitution: UPENN
- Program Director, Adult Cystic Fibrosis & Professor of Medicine at the Hospital of the University of Pennsylvania.
- Manages 250 patients with cystic fibrosis and has prescribed Kalydeco, Orkambi, and Symdeko.
- Research interests include chronic rejection after lung transplantation, gastroesophageal reflux disease in advanced lung disease and lung transplant patients, choice of transplant operation in patients with advanced lung disease, and predictions of outcome in patients with cystic fibrosis and lung transplantation.
Please describe your background and practice setting
Added By: ben_adminHow many patients with Cystic fibrosis do you currently manage?
Added By: ben_adminCan you describe the disease journey of a patient?
Added By: ben_adminHow uniform is your treatment algorithm from patient to patient? What different medications do you currently use?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
